Member Info for TorquayFan

Fair point RW - you posed a question and I've no idea WHY Loz was banned but can you research it please? I'll make this point, your question was phrased in the pejorative - sorta like - guilty until proven innocent on that and with no alternatives, so I smell a Rat (NPI).

I did ask before but take pity ! Please - what is AIMOO ? Be kind - I once asked Inan what PMSL was ? G'night all

Can't remember RW - were you on LSE BB at that time ?
Presumably you have some evidence for the word 'liar' ? Have you researched ?
'Liar' - a word so freely thrown around - consider standing for Parliament ?
I remember incessant exchanges with Inan but I don't read Loz much now - I keep him on 'F' except when curiosity takes over . . . "Disruptive" - in one way or another, Loz is not alone is he ?

Thanks for those links C7 - will have a look later . . .
Try this just for fun - I think you can 'clip' links after the first ? mark and it works.
Come on Scancell !

This repeats that interesting product summary etc but I think there's more comments and financial data - so hope it's of interest . . .

https://seekingalpha.com/article/4294260-ipo-update-biontech-proposes-u-s-ipo-terms?

Vascular 41 minutes in . . . https://www.bbc.co.uk/sounds/play/m0008x96

A fuller report at 7.40 am on "Today" today.

From Vascular's link : "The trial saw 945 patients with advanced melanoma randomised into three groups: 314 patients received the ‘double-hit’ of nivolumab plus ipilimumab".

That's 8.06 am . . .

Vascular - that item is reported in the headlines of "Today" about 8.10 this morning. Thanks.

dust the keyboard with a draft message on screen. Anyway I hope that hangs together ?
Nice weekend all.

It can only help IF their IPO goes well but BNTX are amongst SIX biotechs lining up for October IPOs ! My fingers crossed for them . . . BNTX have a weighty cash burn and a long list of projects -
xcvbnm./"BioNTech is hoping to raise $251 million at $18-$20 per share. For them, the IPO will function
at least partly a way to gather the lost cash that would have come in through a $100 million investment from Hong Kong. BioNTech revealed in their first filing for the IPO in September that the investment was held up, possibly due to the protests in Hong Kong and the US-China trade standoff, but updated IPO filings reveal the cancer company is no longer expecting that investment and have retaken those shares. BioNTech’s mRNA platform has attracted some ?.,mnb8-1230-/notable buzz and investor interest. It will use the bulk of the IPO to push through its trials on advanced melanoma, HPV+ head and neck cancer, and triple-negative breast cancer, along with the trials of four drugs being developed in partnership with Genentech, Sanofi and Genmab. Its target market cap is $4.5 billion."

https://endpts.com/led-by-biontech-six-biotechs-line-up-for-october-ipos/

https://www.fiercebiotech.com/biotech/biontech-guns-for-250m-raise-at-4-5b-valuation-ipo-plan

https://www.labiotech.eu/medical/biontech-nasdaq-ipo/

Thanks Crumbs - will Posters for the other 3 abstracts be up today ?

Ruck yes of course it's a good Restaurant but very spicy food ! Pet mark !

Bobbust - are you buying more definitely, defiantly or both ?
(The last King and the present King are very fond of dogs so they're not eaten much in Th. except maybe border areas, Laos and Kampuchea).

“Targeting citrullinated vimentin and enolase with cytotoxic CD4 T cells relies upon MHC-II expression by tumors, reduces myeloid suppressor cells and directly kills tumor cells” by Scancell, ISA Pharmaceuticals and Nottingham University

“Citrullinated glucose-regulated protein 78 is a candidate target for cancer immunotherapy” by Scancell and Nottingham University

All posters will be made available on the Company’s website, at https://www.scancell.co.uk/scientific-papers-posters " "

That's it !

Scancell to present six posters at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference. Scancell, the developer of novel immunotherapies for the treatment of cancer, will be presenting at the 5th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference, being held at the Espace Grande Arche de la Defense in Paris, France, from 25-28 September 2019.
The 2019 meeting hosted by the Cancer Research Institute (CRI), the Association for Cancer lmmunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) will focus on "Translating Science into Survival," and feature talks from more than 50 leaders in the field covering all areas of inquiry in cancer immunology and immunotherapy.

Starting today, Professor Lindy Durrant, Ph.D., Chief Scientific Officer of Scancell and Professor of Cancer Immunotherapy at the University of Nottingham, and members of her research team will be presenting six posters, including one on FG2811 a new ultra-specific antibody with the ability to induce human stem memory T cell (TSCM) proliferation and differentiation. TSCM cells are a rare subset of white blood cells with the stem cell–like ability to self-renew and have capacity to differentiate into other T cell subsets that proliferate and accelerate anti-tumour immunity. Therefore, FG2811 has the potential to be utilised in vivo for cancer immunotherapy or to provide cells for CAR-T or TCR adoptive cell therapies.

The additional poster presentations contribute to the continued scientific understanding of Scancell’s cancer immunotherapy platform, Moditope®, targeting stress induced post translational modifications (siPTMs). These data are important validators as Scancell advances the lead Moditope programme, Modi-1, towards the clinic and also to the continued preclinical advancement of Modi-2.

The poster presentations are as follows:

“An ultraspecific monoclonal antibody (FG2811) recognises a novel marker on stem memory T cells and induces cell proliferation and differentiation in vitro and in vivo” by Scancell, Nottingham University and Josep Carreras Leukaemia Research Institute

“Post-translationally modified antigens are good targets for cancer immunotherapy but some patients have antigen specific T-regs that may need to be neutralized” by Nottingham University and Scancell

“Improving selection criteria for post translationally modified CD4 epitopes using computer algorithms” by Scancell and Nottingham University

“Carbamylation of lysine residues mediated by MDSCs in the tumour environment make excellent targets for CD4 T cell mediated cancer immunotherapy” by Scancell, Nottingham University and Nottingham Trent University

. . . . . . .

Thanks Bermuda - will listen to that later . . . . .
$8 billion strewth ! Guessing that Eli Lilly got more than just Larotrectinib in that price - maybe not surprising that they're going to charge $12-$33K per month.
Do you know the % of Patients carry this NTRK mutation ? Thanks.

In that BBC report : "Yesterday the drug became the first small molecule to be approved for cancer patients with a particular mutation – in this case NTRK gene fusions – regardless of tumour type." I wonder what we can conclude from that ?

"" 'Revolutionary' new class of cancer drugs approved

A "revolutionary" new class of cancer drug that can treat a wide range of tumours has been approved for use in Europe for the first time. Tumour-agnostic drugs do not care where the cancer is growing in the body as long as it has a specific genetic abnormality inside.

UK doctors testing the drugs said they were "a really exciting thing". They said the approach had the potential to cure more patients and cut side-effects. The drug that has been approved is called larotrectinib.""

https://www.bbc.com/news/health-49798628

I peeped at the 'Abstracts' - there's a stunning amount of research and many contributors to each paper. Some of Scancell's Abstracts have been selected for 'Poster Sessions'. Really good to see not only new Scancell names but also 'outside' contributors in the big 6 . . . .

Under Prof. Lindy, 6 abstracts are listed, I guess that confirms Scancell's total.

A046 / An ultraspecific monoclonal antibody recognises a novel marker on stem memory T cells and induce cell proliferation and differentiation in vitro and in vivo

A185 / Targeting citrullinated vimentin and enolase with cytotoxic CD4 T cells, relies upon MHC-II expression by tumors, reduces myeloid suppressor cells and directly kills tumor cells

A201 / Citrullinated glucose-regulated protein 78 is a can-didate target for cancer immunotherapy

A212 / Post-translationally modified antigens are good targets for cancer immunotherapy but some patients have antigen specific T-regs that may need to be neutralized

B203 / Carbamylation of lysine residues mediated by myeloid derived suppressor cells in the tumor environ-ment make excellent targets for CD4 T cell mediated can-cer immunotherapy

B223 / Improving selection criteria for post translationally modified CD4 epitopes using computer algorithms

I thought B223 most interesting so let's see if that helps our progress. An impressive 'Meet' indeed but WTP, I'm not expecting any commercial news coming or an RNS but you never know.

BioNTech have done well to get one session 'Chair' in place and 3 actual 'Presentations' . . . I'm surprised that Prof. Lindy is not presenting I suppose - she certainly has enough to talk about and a few drums to bang.

Come on Scancell ! GLA

"Bayer wants top dollar for larotrectinib" - you can say that again ! $33,000 pm (that's absolutely shocking !) but there's a refund for Patients who don't get a response . .